Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Voyager Therapeutics Inc VYGR

Voyager Therapeutics, Inc. is a biotechnology company focused on advancing neurogenetic medicines. The Company’s pipeline includes programs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple other diseases of the central nervous system. Many of its programs are derived from its TRACER AAV capsid discovery platform, which is used to generate novel... see more

Recent & Breaking News (NDAQ:VYGR)

Voyager Therapeutics Appoints Grace E. Colón, Ph.D., to its Board of Directors

GlobeNewswire December 14, 2022

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire November 29, 2022

Voyager Therapeutics Reports Third Quarter 2022 Financial and Operating Results

GlobeNewswire November 8, 2022

Voyager Therapeutics Announces Third Quarter 2022 Conference Call and Webcast

GlobeNewswire November 1, 2022

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire October 18, 2022

Voyager Therapeutics Presents Data Characterizing a Novel CNS Receptor and Demonstrating the Low-Dose Potential of TRACER(TM) Generated Capsid Families

GlobeNewswire October 11, 2022

Voyager Therapeutics Announces Pfizer License of Next-Generation AAV Capsid for Rare Neurologic Disease Target

GlobeNewswire October 4, 2022

Voyager Therapeutics Announces Data Presentations at the 29th Annual Congress of the European Society of Gene & Cell Therapy

GlobeNewswire October 3, 2022

Voyager Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire September 27, 2022

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire September 22, 2022

Voyager Therapeutics Appoints Peter Pfreundschuh as CFO; Todd Carter, Ph.D., as Chief Scientific Officer; and Trista Morrison as SVP Corporate Affairs

GlobeNewswire September 7, 2022

Voyager Therapeutics Prioritizes Pipeline and Reports Second Quarter 2022 Financial and Operating Results

GlobeNewswire August 4, 2022

Voyager Therapeutics Presents New Data Demonstrating Novel Candidate Therapeutic Antibodies Reduced Tau Pathology in Multiple Preclinical Models

GlobeNewswire August 3, 2022

Voyager Therapeutics to Present Second Quarter 2022 Results and Corporate Update

GlobeNewswire August 2, 2022

Voyager Therapeutics Appoints Catherine J. Mackey, Ph.D. to its Board of Directors

GlobeNewswire July 28, 2022

Voyager Therapeutics' TRACER(TM) Capsids Demonstrate Enhanced CNS Transduction Across Species; New Preclinical Results Bolster GBA1, Tau, SOD1 ALS Gene Therapy Programs

GlobeNewswire May 19, 2022

Voyager Therapeutics to Present Preclinical Data from its Vectorized anti-HER2 Antibody Program and a Novel AAV5-Derived TRACER(TM) Capsid at the 25th American Society of Gene and Cell Therapy Annual Meeting

GlobeNewswire May 16, 2022

Voyager Therapeutics Reports First Quarter 2022 Financial and Operating Results

GlobeNewswire May 4, 2022

Voyager Therapeutics Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 2022 Annual Meeting

GlobeNewswire May 3, 2022

Voyager Therapeutics Appoints Alfred W. Sandrock, Jr., M.D., Ph.D., as Chief Executive Officer

GlobeNewswire March 22, 2022